Pharmaceutical patent

109 articles available

Forxiga (dapagliflozin), developed by BMS/AstraZeneca, is now making room for generics to squeeze in. In Russia, this process has been dramatically accelerated: the latest court case has ruled that…

The USA truly is a land of innovation. One adult in eight there is currently taking a GLP-1 drug such as Ozempic or Wegovy.1 Within six months, their households spend 5.3% less on groceries and 8%…

In Sanofi and Regeneron v. Amgen, the Düsseldorf Local Division upheld a second medical use patent but dismissed the infringement action. The difficulty was proving that the medicine would be…

The 2026 AIPPI World Congress, held in Hamburg from 7 to 10 October, brought together IP practitioners, judges, industry representatives and academics from around the world. Its patent programme…

A second medical use patent is often seen as an easy target. The Milan section of the UPC Central Division has just shown that it is much harder to hit when the challenger is required to say exactly…

In two of its recent decisions (apixaban and sacubitril-valsartan), the Czech Industrial Property Office (CZ IPO) has considered the application of decision G-2/21 (plausibility) of the Enlarged…

Winning the jurisdiction argument in a long-arm case is not the same as having a claim. On 2 June 2026 the UPC Court of Appeal confirmed that the Mannheim Local Division had been right to hear…

Before the Unified Patent Court, a launch communication leads a double life. It can show that infringement is imminent. It can also fix the moment when the right holder knew enough to ask for…

On March 3, 2026, the Osaka District Court dismissed a patent infringement lawsuit seeking an injunction against a generic drug, addressing an unprecedented question regarding the scope of extended…